Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity

Oncolytic viruses (OVs) encoding various transgenes are being evaluated for cancer immunotherapy. Diverse factors such as cytokines, immune checkpoint inhibitors, tumor-associated antigens, and T cell engagers have been exploited as transgenes. These modifications are primarily aimed to reverse the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jun, Wang, Shaowei, Zhong, Yunhong, Gao, Ming, Tian, Xuezhang, Zhang, Liting, Pan, Dongli, Qin, Qingsong, Wu, Bing, Lan, Ke, Sun, Zhi-Jun, Zhang, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200819/
https://www.ncbi.nlm.nih.gov/pubmed/37223114
http://dx.doi.org/10.1016/j.omto.2023.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200819/
https://www.ncbi.nlm.nih.gov/pubmed/37223114
http://dx.doi.org/10.1016/j.omto.2023.04.006

Ejemplares similares